LUPIN - Lupin | Wealthrox

Lupin

LUPIN · Pharma > Pharmaceuticals & Drugs · Chairman: Manju D Gupta · MD: Nilesh Gupta · Listing date: Sept. 11, 2001 · Employees: 18573 · Mumbai · http://www.lupin.com

Stock Price vs Company Growth

1.3%

2.7%

5.2%

14.2%

10.2%

8.1%

17.5%

10y

3.7%

all

16.2%

🤔 How to analyze this graph?

Last Traded Price

₹ 2,062 1.3%

2,036

2,521

Company Overview

Sales

29,967 Cr

Growth: 21.2%

Profit after Tax

5,529 Cr

Growth: 3.7%

Large Cap

94,286 Cr

P/E: 17.1x

Industry P/E: 35.1x

Fundamentals

Sales (Cr)	₹ 29,967
Growth	21.2%
EBITDA	31.8%
P/S	3.1x
Dividend	0.6%
P/E	17.1x
Book Value	₹ 522
PEG Ratio	0.8x
ROE	25.3%
P/B	4.0x

Shareholding Pattern

Institutions

Life Insurance Corporation Of India

6.99 %

Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund

4.28 %

Government Pension Fund Global

1.21 %

Franklin India Focused Equity Fund

1.13 %

Icici Prudential Life Insurance Company Limited

1.13 %

Promoters

Lupin Investments Pvt Ltd

45.3 %

Manju D Gupta

0.85 %

Nilesh D Gupta

0.2 %

Anuja Gupta

0.16 %

Desh Bandhu Gupta Huf

0.14 %

Others

Rakesh Jhunjhunwala

1.6 %

Nps Trust - A/C Lic Pension Fund Sch-State Govt

1.48 %

Iepf

0.15 %

Increase Decrease No change

Company Profile Detailed

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in many markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S.

Belongs to (65 Indices) view more

Investors (233)

lavneet

nitesh

ishares....

Followers (56)

rehan

yogesh

nitin2